drugset / Trial / NCT06826313
A Study of Intravenous VRT106 for Locally Advanced or Metastatic Solid Tumors
Phase 1
Recruiting
12 enrolled
Guangzhou Virotech Pharmaceutical Co., Ltd.
Third Affiliated Hospital, Sun Yat-Sen University · collab
NaSingle-groupOpen-labelTreatment
Summary
A Phase I Study of the Safety and Tolerability of VRT106 Administered Intravenously for Treatment of Patients With Locally Advanced or MetastaticSolid Tumors
Timeline
- Start
- 2025-03-19
- Primary completion
- 2025-12-30
- Completion
- 2027-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | VRT106 | Unknown | — | Intravenous |